Investors Hangout Stock Message Boards Logo
  • Home
  • Mailbox
  • Boards
  • Favorites
  • Whats Hot!
  • Login - Join Now!
CardioGenics Holdings Inc. CGNH
Posted On: 03/09/2014 7:25:17 AM
Post# of 53
Avatar
Posted By: Stock_Tracker
Latest Cardiogenics Holding (CGNH) Headlines



Small-Cap Specialists Issues New Research Report With Stocks on Watch

Marketwire - Mon Aug 26, 7:01AM CDT

Tucows, Inc. (NYSE MKT: TCX) is a global Internet services company. OpenSRS manages over fourteen million domain names and millions of value-added services through a reseller network of over 13,000 web hosts and ISPs. The company has reported its thirteenth consecutive quarter of revenue growth. Read about TCX's financial results and see a full report on company developments at the following link: http://bit.ly/REPORT-TCX



CardioGenics Announces Commencement of Beta-Site Testing

GlobeNewswire - Wed Aug 21, 8:00AM CDT

Beta-Site Testing of the Company's QL Care(TM) Analyzer and Troponin-I Test Begins in Two Hospitals



CardioGenics Announces Schedule for Beta-Site Testing

GlobeNewswire - Wed Jul 10, 8:00AM CDT

CardioGenics Holdings Inc. (OTCBB:CGNH), developer of the ultra-sensitive QL Care(TM) analyzer, an immunoassay Point-Of-Care analyzer, and other products for the In-Vitro-Diagnostics testing market, announced today that beta-site testing of its QL Care(TM) Analyzer and Troponin-I test is scheduled to commence at hospitals affiliated with Wayne State University during the month of July 2013. The Company expects this testing program to be completed within 8-12 weeks.



CardioGenics Announces Internal Review Board Approval for Beta-Site Testing

PR Newswire - Wed Jun 05, 8:05AM CDT

CardioGenics Holdings Inc. (OTCBB: CGNH), developer of the ultra-sensitive QL Care(TM) analyzer, an immunoassay Point-Of-Care Analyzer, and other products targeting the In-Vitro-Diagnostics testing market, announced today that it has received approval of its clinical testing protocol from the Institutional Review Board of Wayne State University ("IRB"), which approval now enables the Company to commence beta-site testing of its QL Care(TM) Analyzer and first cardiovascular test, Troponin-I.














(0)
(0)









  • New Post - Investors HangoutNew Post

  • Public Reply - Investors HangoutPublic Reply

  • Private Reply - Investors HangoutPrivate Reply

  • Board - Investors HangoutBoard

  • More - Investors HangoutMore

  • Keep Post - Investors HangoutKeep Post
  • Report Post - Investors HangoutReport Post
  • Home - Investors HangoutHome
  • Mailbox - Investors HangoutMailbox
  • Boards - Investors HangoutBoards
  • Favorites - Investors HangoutFavorites
  • Whats Hot! - Investors HangoutWhats Hot!
  • Settings - Investors HangoutSettings
  • Login - Investors HangoutLogin
  • Live Site - Investors HangoutLive Site